EVGN
Price
$1.34
Change
-$0.02 (-1.47%)
Updated
Jul 3 closing price
Capitalization
11.56M
31 days until earnings call
FATE
Price
$1.12
Change
-$0.00 (-0.00%)
Updated
Jul 3 closing price
Capitalization
128.39M
24 days until earnings call
Interact to see
Advertisement

EVGN vs FATE

Header iconEVGN vs FATE Comparison
Open Charts EVGN vs FATEBanner chart's image
Evogene
Price$1.34
Change-$0.02 (-1.47%)
Volume$44.79K
Capitalization11.56M
Fate Therapeutics
Price$1.12
Change-$0.00 (-0.00%)
Volume$1.21M
Capitalization128.39M
EVGN vs FATE Comparison Chart in %
Loading...
EVGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EVGN vs. FATE commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVGN is a Hold and FATE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (EVGN: $1.34 vs. FATE: $1.12)
Brand notoriety: EVGN and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EVGN: 2% vs. FATE: 63%
Market capitalization -- EVGN: $11.56M vs. FATE: $128.39M
EVGN [@Biotechnology] is valued at $11.56M. FATE’s [@Biotechnology] market capitalization is $128.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVGN’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • EVGN’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both EVGN and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVGN’s TA Score shows that 5 TA indicator(s) are bullish while FATE’s TA Score has 3 bullish TA indicator(s).

  • EVGN’s TA Score: 5 bullish, 5 bearish.
  • FATE’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, EVGN is a better buy in the short-term than FATE.

Price Growth

EVGN (@Biotechnology) experienced а +4.69% price change this week, while FATE (@Biotechnology) price change was +1.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

EVGN is expected to report earnings on Aug 06, 2025.

FATE is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($128M) has a higher market cap than EVGN($11.6M). EVGN YTD gains are higher at: -28.342 vs. FATE (-32.121). EVGN has higher annual earnings (EBITDA): -14.42M vs. FATE (-168.28M). FATE has more cash in the bank: 240M vs. EVGN (9.85M). EVGN has less debt than FATE: EVGN (13M) vs FATE (83.3M). FATE has higher revenues than EVGN: FATE (13.3M) vs EVGN (6.77M).
EVGNFATEEVGN / FATE
Capitalization11.6M128M9%
EBITDA-14.42M-168.28M9%
Gain YTD-28.342-32.12188%
P/E Ratio0.30N/A-
Revenue6.77M13.3M51%
Total Cash9.85M240M4%
Total Debt13M83.3M16%
FUNDAMENTALS RATINGS
EVGN vs FATE: Fundamental Ratings
EVGN
FATE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
14
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
6164
P/E GROWTH RATING
1..100
91100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (14) in the Biotechnology industry is in the same range as EVGN (36). This means that FATE’s stock grew similarly to EVGN’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EVGN (100). This means that FATE’s stock grew similarly to EVGN’s over the last 12 months.

FATE's SMR Rating (96) in the Biotechnology industry is in the same range as EVGN (100). This means that FATE’s stock grew similarly to EVGN’s over the last 12 months.

EVGN's Price Growth Rating (61) in the Biotechnology industry is in the same range as FATE (64). This means that EVGN’s stock grew similarly to FATE’s over the last 12 months.

EVGN's P/E Growth Rating (91) in the Biotechnology industry is in the same range as FATE (100). This means that EVGN’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVGNFATE
RSI
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
83%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 6 days ago
85%
Declines
ODDS (%)
Bearish Trend 11 days ago
89%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
86%
Aroon
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 4 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
EVGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NPPTF1.040.01
+0.97%
Neptune Digital Assets Corp.
MAMTF14.20N/A
N/A
Mcan Mortgage Corp
SUEZY6.10N/A
N/A
Suedzucker AG
TYBT87.00N/A
N/A
Trinity Bank, N.A
SONVY59.29-0.80
-1.34%
Sonova Holding AG

EVGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVGN has been loosely correlated with CARM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if EVGN jumps, then CARM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVGN
1D Price
Change %
EVGN100%
-1.47%
CARM - EVGN
58%
Loosely correlated
-4.05%
INSM - EVGN
32%
Poorly correlated
N/A
PMVP - EVGN
31%
Poorly correlated
+8.18%
AXON - EVGN
30%
Poorly correlated
+2.70%
FATE - EVGN
29%
Poorly correlated
N/A
More